Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222872 · ClinicalTrials.gov registry record · Phase 1
3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women
A Phase 1 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT00222872 is a Phase 1 study of Osteoporosis and Osteoporosis, Postmenopausal that has completed, run by University of Pittsburgh. The registered enrollment target is 61 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00222872, a Phase 1 study of Osteoporosis and Osteoporosis, Postmenopausal, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to determine the safety and effectiveness of three week daily subcutaneous injections of Parathyroid Hormone-related Protein (1-36). Previous studies indicated that PTHrP has a skeletal 'anabolic' or bone-building effect, and has shown to increase bone mineral density in postmenopausal women with osteoporosis. Safety of PTHrP will be determined by measurements of blood pressure and pulse, serum blood calcium levels and subjective symptoms. Effectiveness will be measured by changes in measurements of blood and urine markers of bone turnover.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Parathyroid Hormone-related Protein
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222872
The ClinicalTrials.gov registry entry for NCT00222872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00222872 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00222872 about?
NCT00222872 is a clinical study titled "3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women". The main purpose of this study is to determine the safety and effectiveness of three week daily subcutaneous injections of Parathyroid Hormone-related Protein (1-36). Previous studies indicated that PTHrP has a skeletal 'anabolic' or bone-building effect, and has shown to increase bone mineral densi...
What is the current status of trial NCT00222872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2005-07. Estimated completion is 2008-09.
What conditions does trial NCT00222872 study?
This clinical trial studies the following conditions: Osteoporosis, Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT00222872?
The interventions under investigation include: Placebo (DRUG), Parathyroid Hormone-related Protein (DRUG).
Who is sponsoring clinical trial NCT00222872?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00222872 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.